1. Home
  2. FLGT vs ATYR Comparison

FLGT vs ATYR Comparison

Compare FLGT & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FLGT
  • ATYR
  • Stock Information
  • Founded
  • FLGT 2011
  • ATYR 2005
  • Country
  • FLGT United States
  • ATYR United States
  • Employees
  • FLGT N/A
  • ATYR N/A
  • Industry
  • FLGT Medical Specialities
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FLGT Health Care
  • ATYR Health Care
  • Exchange
  • FLGT Nasdaq
  • ATYR Nasdaq
  • Market Cap
  • FLGT 587.3M
  • ATYR 535.0M
  • IPO Year
  • FLGT 2016
  • ATYR 2015
  • Fundamental
  • Price
  • FLGT $21.88
  • ATYR $6.03
  • Analyst Decision
  • FLGT Buy
  • ATYR Strong Buy
  • Analyst Count
  • FLGT 3
  • ATYR 5
  • Target Price
  • FLGT $25.33
  • ATYR $23.25
  • AVG Volume (30 Days)
  • FLGT 204.3K
  • ATYR 4.9M
  • Earning Date
  • FLGT 11-07-2025
  • ATYR 11-06-2025
  • Dividend Yield
  • FLGT N/A
  • ATYR N/A
  • EPS Growth
  • FLGT N/A
  • ATYR N/A
  • EPS
  • FLGT N/A
  • ATYR N/A
  • Revenue
  • FLGT $303,223,000.00
  • ATYR N/A
  • Revenue This Year
  • FLGT $15.19
  • ATYR $478.72
  • Revenue Next Year
  • FLGT $10.58
  • ATYR $1,899.26
  • P/E Ratio
  • FLGT N/A
  • ATYR N/A
  • Revenue Growth
  • FLGT 4.31
  • ATYR N/A
  • 52 Week Low
  • FLGT $14.57
  • ATYR $1.67
  • 52 Week High
  • FLGT $23.56
  • ATYR $7.29
  • Technical
  • Relative Strength Index (RSI)
  • FLGT 56.24
  • ATYR 62.69
  • Support Level
  • FLGT $21.50
  • ATYR $5.08
  • Resistance Level
  • FLGT $22.37
  • ATYR $5.77
  • Average True Range (ATR)
  • FLGT 0.53
  • ATYR 0.47
  • MACD
  • FLGT -0.09
  • ATYR 0.04
  • Stochastic Oscillator
  • FLGT 45.52
  • ATYR 68.03

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Share on Social Networks: